Chaperon Participates in Global Healthcare Conference... "Presentation of Clinical Results"

Chaperon announced on the 23rd that it has been invited to the 'BFC Global Healthcare Conference' (hereinafter BFC Conference) to be held in San Francisco, USA, on January 12, 2025, where it will present clinical results of its core pipeline. At this conference, Chaperon will focus on the clinical results of the Phase 2b Part 1 trial of the atopic dermatitis treatment 'NuGel,' currently underway in the United States, and will actively initiate discussions on technology transfer for its major pipelines.

The BFC Conference, now in its 8th year, is a global event that provides insights into the bio and healthcare industry trends in the US, Europe, and Asia, and serves as a platform to discuss licensing out and collaboration opportunities among companies. More than 750 representatives from global pharmaceutical and biotech companies participated in the last conference held earlier this year, and even more attendees are expected this time.

The BFC Group, headquartered in Shanghai, is a healthcare-focused investment bank engaged in technology transfer, capital raising, mergers and acquisitions, and strategic consulting. The BFC Group consults for over 300 companies across more than 30 countries worldwide. To date, it has successfully closed over 100 deals, facilitating technology transfers worth more than 14 trillion KRW, making it a leading global investment bank.

Notably, this year, the group successfully negotiated the technology transfer of Chengdu Baiyu Pharmaceutical's technology to Novartis. It also facilitated the transfer of TJ Biopharma's technology to Sanofi.

At this event, Chaperon will introduce its key pipelines including the atopic dermatitis treatment NuGel, the Alzheimer's treatment NuCerin, and the immuno-oncology agent 'Papiliximab.' The company plans to disclose the Phase 2b Part 1 clinical results of NuGel currently underway in the US, attracting attention from global pharmaceutical companies. Based on these data, Chaperon intends to proceed with active technology transfer discussions with global companies awaiting clinical outcomes.

NuGel, the atopic dermatitis treatment, is a novel drug with a differentiated mechanism that suppresses the skin's inflammatory complex to treat atopic symptoms. The Phase 2b trial in the US, conducted on diverse ethnic groups, has completed dosing for all patients as scheduled this month. The dosing was up to eight times higher than that of the Phase 2a clinical trial conducted in Korea, and based on these results, two dosing levels will be selected for the Phase 2b Part 2 trial. The company explained that the Safety Monitoring Committee (SMC) will review the Phase 2b Part 1 trial in early January next year, followed by the commencement of the Part 2 clinical trial.

A Chaperon representative stated, “The Phase 2b Part 1 trial was conducted with FDA approval in the US on diverse ethnic groups and involved stepwise dose escalation to monitor patient conditions, allowing us to identify major adverse reactions in the high-dose group.” He added, “We expect that this trial will enable us to understand the trends in atopic dermatitis treatment in the high-dose group.”

He continued, “At this BFC Conference, we will not only deliver oral presentations to many multinational pharmaceutical companies but also introduce our core pipelines through individual meetings. Furthermore, we will accelerate technology transfer discussions for NuGel and various other pipelines based on the latest clinical results.”